Fairmount Ventures’ Post

Innovation in healthcare and life sciences is the heartbeat of a healthier, sustainable future. But what strides have been made in Swiss and global life sciences? We reflect on 2023, celebrate Switzerland's commitment to precision and excellence, and look to the future of life sciences. 👉 Read the Article: https://lnkd.in/dvfFxV6P Don't be a spectator; be a contributor to the future of life sciences. Speak to one of our experts at Swisslinx about opportunities in driving innovation and making a meaningful impact. Your next career milestone could be just a click away. 🚀 #swisslinx #swisslinxinsights #LifeSciences #HealthcareInnovation #Swisslinx #CareerOpportunities #Innovation2024

In this insightful interview, Rebecca Willumson from Fierce Biotech convenes with two distinguished experts: Mary Claire Duch, Deputy Group President of Real Chemistry, and Kathleen Tregoning, Chief Corporate Affairs Officer at Cerevel Therapeutics. Together, they share their perspectives on the current state of affairs, highlighting the buzz surrounding recent advancements in neuroscience, as well as the role of AI and other technological innovations in enhancing patient engagement. The discussion also emphasizes the importance of conveying clear, concise, and reliable information, underscoring the responsibility of communications professionals to ensure that accurate messages are delivered to doctors, patients, and the broader community. They delved into the dynamic landscape of neuroscience, the pivotal role of AI and technology in patient engagement, and the crucial need for clear and reliable healthcare information. 🔗 For the full interview, visit: https://lnkd.in/gRknW3RA 📣 Keep up with the latest from the #FierceBiotechSummit and all related events by following Fierce Life Sciences Events. #FierceBiotechSummit #WeAreFierce #FiercePharma #RealChemistry

I take pride in the sentence: "Jill of all trades, master of some." It took years for the master of "some" to take shape but here we are in 2024. Anyone out there want to discuss the latest trends in #cellandgenetherapy? Did you know the C&G therapy market is forecasted to grow to $35.4B by 2026, representing a CAGR of 22%?* https://lnkd.in/ewKsEWQF I will continue to post about various topics but in the meantime, I wanted to share more about my "trades" as I job hunt: My undergraduate/Masters degrees in Psychology (and Non-profit Management) help any team in sales, communication, strategy & all business functions. While I do not posses a degree in biology or life sciences, I have always been able to quickly learn science/technical leaning concepts and break them down in a simplified way to a customer or client. My early career was in IT/SaaS and the nonprofit sector where I learned technical skills, marketing, strategic planning & how to lead teams. My transition to the medical sector led me to Medisys USA which exposed me to science-leaning concepts such as biologics and medical devices in the spine, orthopedic and ocular spaces. Charter Medical, LLC opened me up to the life sciences/biopharma space where I learned the basics of cell & gene therapy, in vivo vs ex vivo, autologous vs allogenic, and many more. In my last role, I worked with engineers, field application specialists & clients on custom projects and served as the liaison to the customer on custom cell therapy solutions, working with many different cell types and research projects. I love to learn and intuitively look at the bigger picture in any business. Thank you to the following people who have helped me or have offered to help in the past few months with my job search. I will continue to engage with your content and promote your brands, businesses and services and hope to get to know you all better professionally: Josie Hayes PhD, PCCC & Josh Ludwig- for the insights into my skillsets Anis Fahandej-Sadi - for the support and consulting Ken Pasko | Silke Grainger | Britt Steed, M.Sc. | David Lewandowski- for the willingness to help a new connection Amber Penrose- for being a life science recruiter who is taking direct action on my behalf Claire LePage- for continuing to follow up with a client about a role for me Jack Hench- for always being a sounding board Diane Maragos- for my new friend and connection in this space. Congrats again on your new role Univo IRB *(Source: https://lnkd.in/eC8gW9ns) #opentowork #sales #businessdevelopment #accountmanagement #medical #lifesciences #cellandgenetherapy #bioprocessing #biopharma ➕ Follow my profile 🔔 Click the bell for notifications 🤝 Connect with me 💬 Send a message 👍 Like this post ♻ Repost it to your network ⬇️ Comment below

The 42nd J.P. Morgan Healthcare Conference took place in San Francisco recently, bringing together industry leaders, healthcare innovators, executives and investors to share latest developments, ideas and products and to explore potential investment opportunities.   In Stephenson Harwood's latest life sciences A-Z update, Naomi Leach, Alexandra Pygall and Alice Routh have summarised some of the key trends identified during the conference and look forward to the year ahead and the opportunities it is likely to bring. #LifeSciences

In our latest life sciences A-Z update, we have summarised the key trends identified at JPM: advanced AI; cell & gene therapy; ADCs & radiopharmaceuticals; and obesity.

CBRE's 2024 U.S. Life Sciences Talent Trend report highlights The Columbus Region as a top R&D market. Notably, Ohio stands out with three or more life sciences labor clusters nationwide, showcasing a strong ecosystem. Eddie Pauline, Ohio Life Sciences attributes this success to strategic investments in talent and the overall life sciences landscape. Dive deeper into the insights in Carrie Ghose's article on Columbus Business First & explore the full report here: https://lnkd.in/gVaZS85v

🌟 Exciting Announcement for Leaders & Innovators in Pharma, Biotech, and Tech! 🌟 🚀 Diving into New Frontiers! 🚀 Are you part of a Large Organization in Pharma, Biotech, or Tech sectors looking to explore or expand into groundbreaking markets? Or perhaps you're a scientist or bio-founder on the brink of your next big discovery? 🔬 Introducing Our Inaugural Newsletter! 🔬 We're thrilled to announce the launch of our first-ever newsletter, tailored specifically for pioneers like you! This isn't just another industry roundup. We're delving deep into the rapidly evolving realms of Cell and Gene Therapy, RNA Therapeutics, Radiopharmaceuticals, and beyond. 🌍 Beyond Science: Advocating for Health Equality 🌍 In a world where Diversity and Inclusion are paramount, we commit to not only exploring cutting-edge science and technology but also how these advances can foster Health Equality across communities. 🔍 Why Subscribe? Exclusive insights into Therapeutics, Tools, Technology, and Services shaping the future. Deep dives into RNA Therapeutics and Radiopharmaceuticals — the next frontier in medicine. Critical discussions on Health Equality, and why Diversity & Inclusion are essential in Life Sciences. 👥 Join Our Community of Forward-Thinkers 👥 Be part of a community dedicated to making significant impacts in the fields of science and technology, all while paving the way for a more inclusive and equitable future. 📬 Subscribe for Free Today! 📬 Don't miss out on this opportunity to stay ahead of the curve. Subscribe now to CharaBio's Newsletter and transform the way you see the future of science and technology. Let's embark on this journey together. #LifeSciences #Biotech #Pharma #TechInnovation #HealthEquality #DiversityInScience #GeneTherapy #RNATherapeutics #Radiopharmaceuticals #Innovation #SubscribeNow

In a recent article for MedCity News, my colleague John Khoury and I explore the rapid growth of the #cellandgenetherapy industry, which despite economic challenges pulled in $11.7 billion in investments in 2023. We emphasize the critical role of informed #portfoliomanagement decisions in unlocking success, highlighting the importance of asset assessment and strategic alignment. By prioritizing R&D initiatives, effectively addressing societal needs, and embracing emerging technologies, companies can navigate market uncertainties and drive innovation in this competitive sector. For more insights into portfolio management strategies, read the full article on MedCity News.

🚀 Exciting Collaboration Opportunity in the Cutting-Edge Field of CRISPR Diagnostics for Infectious Disease Pathogens! 🚀 Hello, LinkedIn community! I'm David Omofonma, an innovator passionate about harnessing the power of CRISPR technology to revolutionize diagnostics. My project focuses on developing a novel CRISPR-based diagnostic device that combines rapid detection capabilities and multiplexing capabilities with the precision of microfluidics technology. This device aims to dramatically improve point-of-care diagnostics and at-home testing, making it quicker, more accurate, and accessible to all. 🌟 **Why Collaborate?** - **Groundbreaking Research**: Be part of a pioneering project at the forefront of diagnostics. - **Shared Success**: Potential for co-ownership on both publications and the resulting product, opening doors to new research funding and commercialization opportunities. 🔍 **Looking For**: - A research collaborator with expertise in CRISPR diagnostics and/or microfluidics. - A lab partnership for concept validation, offering the chance to apply cutting-edge science to solve real-world health challenges. This is more than just a research project; it's an opportunity to impact global health outcomes positively. Whether you're a seasoned researcher, a lab looking to contribute to meaningful innovation, or an investor interested in the next big thing in healthcare, I'd love to connect and explore how we can make a difference together. Interested? Let's talk! Drop me a message or comment below. Together, let's pave the way for a healthier future. #CRISPR #Diagnostics #Innovation #HealthTech #Collaboration #biotechnology

Today BioSpace is releasing our third report investigating attitudes, perspectives and experiences of the life sciences workforce as they relate to #DEIB. It is so interesting to see how the workforce is evolving both in terms of representation, attitudes and perspectives. Given how differently groups of people experience work, it's also clear to me that there is still work to be done to create cohesive, inclusive workplaces. Download the free report: https://lnkd.in/gBCA4x96 We will be talking about how biopharma DEIB strategies are evolving in our webinar tomorrow, The Future of DEIB: Evolving Philosophies & Strategies. You can register for that here: https://lnkd.in/g_i7SrW7